TrialCancer2021

Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study.

Sagar Lonial et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.